Enliven Therapeutics, Inc. - Common Stock (ELVN)

CUSIP: 29337E102

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 7 signals
Share change
+264,061
Put/Call ratio
450%
SEC-reported price per share
$19.68
Number of holders
118
Value change
+$4,352,699
Number of buys
61
Open additional details 1 more signal available
Number of sells
47
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
73,332,127

Security key

29337E102

Report period

Q1 2025

Institutions

118

Top holders

10

Ownership snapshot

Top reported holders of ELVN - Enliven Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Commodore Capital LP
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
0/15
Latest evidence
31 Dec 2024
13F 3/4/5 Highest disclosed value: $179,089,605 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC has the largest disclosed position value at $179.09M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.
Disclosed position value Top 5
Commodore Capital LP $94.61M
David P. Bonita $63.55M
5AM Partners VI, LLC $57.16M
New Enterprise Associates 14, L.P. $39.52M
RA CAPITAL MANAGEMENT, L.P. $32.12M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Commodore Capital LP
13F 3/4/5
Company · 10%+ Owner
—
denominator unverified
$94,612,500
4,205,000 shares
— 31 Dec 2024
David P. Bonita
3/4/5
Director, 10%+ Owner
—
mixed-class rows
$63,552,894
4,207,568 shares
mixed-class rows
— 02 Jun 2022
5AM Partners VI, LLC
3/4/5
10%+ Owner
—
denominator unverified
$57,156,028
3,835,975 shares
— 14 Feb 2024
New Enterprise Associates 14, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$39,518,242
2,611,050 shares
— 05 Apr 2022
RA CAPITAL MANAGEMENT, L.P.
3/4/5 13F
Former 10% owner · Company
—
denominator unverified
$32,123,508
2,122,465 shares
— 23 Feb 2023
Braden M. Leonard
3/4/5
10%+ Owner
—
denominator unverified
$30,236,309
1,997,774 shares
— 03 Jan 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
118
Shares
49,886,849
Rows available
118
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2025 vs Q1 2025 Across Filers

Q1 2025 holders
118
Q1 2025 holders
118
Holder diff
0
Investor Q1 2025 Shares Q1 2025 Shares Share Diff Share Chg % Q1 2025 value Q1 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .